Cargando…

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy

Cancer stem cell (CSC) and ATP-binding cassette (ABC) transporters are associated with treatment resistance and outcomes of patients with cancer. The present study investigated the prognostic implications of pre-therapeutic expression of ABC transporters and CSC markers in patients with colon cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Song-Hee, Kim, Jin Won, Kim, Milim, Kim, Jee Hyun, Lee, Keun-Wook, Kim, Bo-Hyung, Oh, Heung-Kwon, Kim, Duck-Woo, Kang, Sung-Bum, Kim, Hyunchul, Shin, Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507487/ https://www.ncbi.nlm.nih.gov/pubmed/31186779 http://dx.doi.org/10.3892/ol.2019.10234

Ejemplares similares

Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
por: Cho, Jung Rae, et al.
Publicado: (2022)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy
por: An, Min Sung, et al.
Publicado: (2015)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Impact of Postoperative Chemoradiotherapy versus Chemotherapy Alone on Recurrence and Survival in Patients with Stage II and III Upper Rectal Cancer: A Propensity Score-Matched Analysis
por: Song, Changhoon, et al.
Publicado: (2015)

Adjuvant FOLFOX treatment for stage III colon cancer: how many cycles are enough?
por: Tsai, Yi-Jian, et al.
Publicado: (2016)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
por: Lee, Jii Bum, et al.
Publicado: (2020)

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting
por: Kim, Chee Young, et al.
Publicado: (2015)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients
por: Zhou, Meijiao, et al.
Publicado: (2022)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX
por: Kim, Mi-Jung, et al.
Publicado: (2016)

Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer
por: Degirmencioglu, Serkan, et al.
Publicado: (2019)

A Case of Acute Encephalopathy After the Initiation of FOLFOX Chemotherapy in a Patient With Colon Cancer
por: Kim, Jin S, et al.
Publicado: (2023)

Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy
por: Koo, Taeryool, et al.
Publicado: (2015)

The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
por: André, Thierry, et al.
Publicado: (2013)

Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients
por: Lee, Dae-Won, et al.
Publicado: (2015)

The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

Changes in Body Composition during Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer
por: Chung, Eric, et al.
Publicado: (2019)

Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
por: Kim, Jieun, et al.
Publicado: (2021)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes for prediction of prognosis in resected colon cancer
por: Lim, Yoojoo, et al.
Publicado: (2023)

Programmed cell death ligand‐1 protein expression and CD274/PD‐L1 gene amplification in colorectal cancer: Implications for prognosis
por: Lee, Kyu Sang, et al.
Publicado: (2018)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
por: Murray, Nigel P, et al.
Publicado: (2019)

Comparison of Compliance of Adjuvant Chemotherapy Between Laparoscopic and Open Surgery in Patients With Colon Cancer
por: Chun, Kan Ho, et al.
Publicado: (2014)

Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis
por: Lee, Yoontaek, et al.
Publicado: (2018)

Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial
por: Lee, Kyung Ha, et al.
Publicado: (2023)

Isolation and Characterization of the Colletotrichum acutatum ABC Transporter CaABC1
por: Kim, Suyoung, et al.
Publicado: (2014)

Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer
por: Huang, Wen-Yen, et al.
Publicado: (2017)

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2019)

Adjuvant Chemotherapy in Microsatellite Instability–High Gastric Cancer
por: Kim, Jin Won, et al.
Publicado: (2020)

Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System
por: Song, Changhoon, et al.
Publicado: (2018)

Prevotella contributes to individual response of FOLFOX in colon cancer
por: Hou, Xiao‐Ying, et al.
Publicado: (2021)

Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer
por: Lee, Mok-Won, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1q8taeh2jec3o6lkvqrl7a1nfh